Fig. 3From: RECIST and CHOI criteria in the evaluation of tumor response in patients with metastatic colorectal cancer treated with regorafenib, a prospective multicenter studyOverall survival as a function of (a) RECIST and (b) Choi criteria at 2 months in the ITT2 populationBack to article page